Journal Club: Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27754915.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Transient headache exacerbation during IV dihydroergotamine (DHE) therapy of migraine may prompt clinicians to prematurely discontinue DHE therapy, potentially depriving patients of the full benefit of DHE infusion. In a recent Neurology® article, Eller et al. evaluated whether or not worsening headache during DHE infusion was associated with suboptimal medium-term headache outcomes.
Medical subject headings
- Analgesics, Non-Narcotic
- Dihydroergotamine